← All trials
NCT04973527
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- Jun 15, 2023
- Completion date
- Jun 15, 2023
- First posted
- Jul 22, 2021
- Last posted
- Jul 22, 2021
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beijing Boren HospitalLead sponsor
- GenScriptCollaborator
- Beijing Boren HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.